Nima Farzan, Kinnate Biopharma CEO

Kin­nate Bio­phar­ma touts ear­ly ef­fi­ca­cy in pan-RAF pro­gram: #AACR23

OR­LAN­DO — Af­ter suf­fer­ing two de­lays last year, Kin­nate Bio­phar­ma is of­fer­ing an ear­ly-stage look at its monother­a­py pan-RAF in­hibitor, while de­pri­or­i­tiz­ing a pre­clin­i­cal pro­gram to hone in on more ad­vanced pro­grams.

Cur­rent­ly avail­able RAF in­hibitors such as No­var­tis’ Tafin­lar, Pfiz­er’s Braftovi and Roche’s Zelb­o­raf tar­get class I BRAF ki­nase mu­ta­tions. Kin­nate’s exarafenib, on the oth­er hand, was de­signed to al­so tar­get class II and III mu­ta­tions, which con­sti­tute rough­ly 55% of onco­genic BRAF mu­ta­tions, ac­cord­ing to the com­pa­ny.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.